Self-System Therapy for Older Adults With Lung Cancer

Status Completed

Clinical Trial Summary

The purpose of this study to use Self-system therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).

Clinical Trial Description

The investigator will examine whether delivering the SST intervention will be both feasible and acceptable to study participants. The investigator will also examine whether participation in SST can help alleviate symptoms of depression and distress while helping improve overall functioning in older adults with advanced lung cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04057196
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	April 2, 2020
Completion date	June 24, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03668496` - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC	Phase 3
Active, not recruiting	`NCT03322072` - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating	N/A
Recruiting	`NCT05497973` - Psychosocial eHealth in Advanced Lung Cancer	N/A
Recruiting	`NCT06076005` - Lung Cancer ID (Identity) Study
Recruiting	`NCT05860296` - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers	Phase 1/Phase 2
Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
Completed	`NCT04825912` - Resilience Measurement in Older Adults With Late-Stage Lung Cancer	N/A
Completed	`NCT03529851` - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients	N/A
Completed	`NCT03558165` - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed	`NCT03076164` - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	Phase 1/Phase 2
Not yet recruiting	`NCT03153358` - Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation	Phase 2
Recruiting	`NCT04595734` - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting	`NCT04519983` - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs	Phase 2
Not yet recruiting	`NCT05701384` - Lazertinib 160mg in EGFR T790M NSCLC	Phase 2
Withdrawn	`NCT03409341` - Personalizing Immune Checkpoint Inhibitor Therapy
Active, not recruiting	`NCT03728361` - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer	Phase 2
Not yet recruiting	`NCT06024941` - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer	Phase 2
Recruiting	`NCT04669223` - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion	N/A
Recruiting	`NCT05996263` - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Recruiting	`NCT06000358` - The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer	N/A